[177Lu]Lu-DOTA-EB-TATE与[177Lu]Lu-DOTA-TOC的个体内比较
在5例进展性生长抑素受体阳性、计划行放射性核素治疗的患者中,个体内比较[177Lu]Lu-DOTA-EB-TATE与[177Lu]Lu-DOTA-TOC的药代动力学。结果显示[177Lu]Lu-DOTA-EB-TATE在多数患者中肿瘤剂量更高,但肾脏、脾脏和肝脏剂量也更高,肿瘤与关键器官吸收剂量比在多数患者中反而以[177Lu]Lu-DOTA-TOC更高。结论提示使用[177Lu]Lu-DOTA-EB-TATE前需个体化评估其是否优于已有药物。
要点
- 5例患者中4例肿瘤剂量以[177Lu]Lu-DOTA-EB-TATE更高(中位比值1.7,范围0.9-3.9)。
- 所有患者肾脏(中位比值3.2)和脾脏(中位比值4.7)剂量均以[177Lu]Lu-DOTA-EB-TATE更高。
- 5例中4例肿瘤与关键器官吸收剂量比以[177Lu]Lu-DOTA-TOC更高。
核心结论
- 使用[177Lu]Lu-DOTA-EB-TATE前应个体化评估该化合物是否优于已有药物。
研究设计与样本
- 个体内比较5例进展性生长抑素受体阳性、计划行放射性核素治疗的患者中[177Lu]Lu-DOTA-EB-TATE与[177Lu]Lu-DOTA-TOC的器官和肿瘤活性动力学。
主要发现
- 与[177Lu]Lu-DOTA-TOC相比,[177Lu]Lu-DOTA-EB-TATE在5例中4例肿瘤每 administered activity 剂量更高(中位比值1.7,范围0.9-3.9)。
- 所有患者肾脏剂量(中位比值3.2,范围1.6-9.8)和脾脏剂量(中位比值4.7,范围1.2-6.2)均以[177Lu]Lu-DOTA-EB-TATE更高。
- 4例可评估患者中3例肝脏剂量以[177Lu]Lu-DOTA-EB-TATE更高(中位比值4.0,范围0.7-4.9)。
- 5例中4例肿瘤与关键器官吸收剂量比以[177Lu]Lu-DOTA-TOC更高。
临床怎么用
- 在考虑使用[177Lu]Lu-DOTA-EB-TATE治疗前,应个体化评估其是否优于[177Lu]Lu-DOTA-TOC等已有药物。
局限性
- 样本量仅5例,结果需在更大样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The radiolabelled somatostatin analogue [177Lu]Lu-DOTA-EB-TATE binds to albumin via Evans blue, thereby increasing the residence time in the blood and potentially allowing more therapeutic agent to be absorbed into the target tissue during peptide receptor radionuclide therapy. It was tested in selected patients whether the substance is superior to [177Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in organs and tumours after [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC were compared intraindividually in five patients with progressive somatostatin receptor-positive disease scheduled for radionuclide therapy. RESULTS: In comparison to [177Lu]Lu-DOTA-TOC, tumour doses per administered activity were higher for [177Lu]Lu-DOTA-EB-TATE in 4 of 5 patients (median ratio: 1.7; range: 0.9 to 3.9), kidney doses (median ratio: 3.2; range: 1.6 to 9.8) as well as spleen doses (median ratio: 4.7; range 1.2 to 6.2) in all patients, and liver doses in 3 of 4 evaluable patients (median ratio: 4.0; range: 0.7 to 4.9). The tumour to critical organs absorbed dose ratios were higher after [177Lu]Lu-DOTA-TOC in 4 of 5 patients. CONCLUSIONS: Prior to a treatment with [177Lu]Lu-DOTA-EB-TATE, it should be assessed individually whether the compound is superior to established substances.
引用
- Hänscheid H, Hartrampf PE, Schirbel A, et al. Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC. Eur J Nucl Med Mol Imaging. 2021. PMID: 33452632. doi:10.1007/s00259-020-05177-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。